12:00 AM
Sep 16, 2002
 |  BioCentury  |  Product Development

NMDA outlook

NMDA outlook

Company Product Description Indication Status Partners
AstraZeneca AZD4282 (oral glycine) NMDA antagonist Neuropathic pain In clinic
Avanir Neurodex (AVP-923)

Read the full 170 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >